Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells1

Due to their potent immunostimulatory capacity, dendritic cells (DC) have become the centerpiece of many vaccine regimens. Immature DC (DCimm) capture, process, and present Ags to CD4+ lymphocytes, which reciprocally activate DCimm through CD40, and the resulting mature DC (DCmat) loose phagocytic capacity, but acquire the ability to efficiently stimulate CD8+ lymphocytes. Recombinant vaccinia viruses (rVV) provide a rapid, easy, and efficient method to introduce Ags into DC, but we observed that rVV infection of DCimm results in blockade of DC maturation in response to all activation signals, including CD40L, monocyte-conditioned medium, LPS, TNF-α, and poly(I:C), and failure to induce a CD8+ response. By contrast, DCmat can be infected with rVV and induce a CD8+ response, but, having lost phagocytic activity, fail to process the Ag via the exogenous class II pathway. To overcome these limitations, we used the CMV protein pp65 as a model Ag and designed a gene containing the lysosomal-associated membrane protein 1 targeting sequence (Sig-pp65-LAMP1) to target pp65 to the class II compartment. DCmat infected with rVV-Sig-pp65-LAMP1 induced proliferation of pp65-specific CD4+ clones and efficiently induced a pp65-specific CD4+ response, suggesting that after DC maturation the intracellular processing machinery for class II remains intact for at least 16 h. Moreover, infection of DCmat with rVV-Sig-pp65-LAMP1 resulted in at least equivalent presentation to CD8+ cells as infection with rVV-pp65. These results demonstrate that despite rVV interference with DCimm maturation, a single targeting vector can deliver Ags to DCmat for the effective simultaneous stimulation of both CD4+ and CD8+ cells.

[1]  M. Fukuda.  Lysosomal Membrane Glycoproteins , 2001 .

[2]  R. Steinman,et al.  The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells , 2000, The Journal of experimental medicine.

[3]  R. Steinman,et al.  Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. , 1999, Journal of immunology.

[4]  A. Lanzavecchia,et al.  Inhibition of dendritic cell maturation by herpes simplex virus , 1999, European journal of immunology.

[5]  V. Verhasselt,et al.  Trypanosoma cruzi Infects Human Dendritic Cells and Prevents Their Maturation: Inhibition of Cytokines, HLA-DR, And Costimulatory Molecules , 1999, Infection and Immunity.

[6]  S. Riddell,et al.  Deficient cellular immunity--finding and fixing the defects. , 1999, Science.

[7]  A. Pain,et al.  Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells , 1999, Nature.

[8]  Hanno Langen,et al.  Maturation, Activation, and Protection of Dendritic Cells Induced by Double-stranded RNA , 1999, The Journal of experimental medicine.

[9]  Geoffrey L. Smith,et al.  Vaccinia virus immune evasion. , 1999, Immunology letters.

[10]  R. Steinman,et al.  Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells , 1998, The Journal of experimental medicine.

[11]  Loise M. Francisco,et al.  Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[12]  D. Wright,et al.  Melanoma vaccines. , 1998, Environmental health perspectives.

[13]  A. Lanzavecchia.  Licence to kill , 1998 .

[14]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[15]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[16]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[17]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[18]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[19]  Scott R. Burrows,et al.  Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4+ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design , 1998, Journal of Virology.

[20]  C. Kurts,et al.  CD4+ T Cell Help Impairs CD8+ T Cell Deletion Induced by Cross-presentation of Self-Antigens and Favors Autoimmunity , 1997, The Journal of experimental medicine.

[21]  A. Alcamí,et al.  Vaccinia virus immune evasion , 1997, Immunological reviews.

[22]  J. York,et al.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. , 1997, Blood.

[23]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[24]  R. Steinman,et al.  Developmental regulation of MHC class II transport in mouse dendritic cells , 1997, Nature.

[25]  C. Kurts,et al.  Class I–restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8+ T Cells , 1997, The Journal of experimental medicine.

[26]  F. Marincola,et al.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Siliciano,et al.  The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway* , 1997, The Journal of Biological Chemistry.

[28]  R. Steinman,et al.  Dendritic cells as immunogens for human CTL responses. , 1997, Advances in experimental medicine and biology.

[29]  J. Thompson,et al.  Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. , 1996, Journal of immunology.

[30]  J. Suttles,et al.  The many roles of CD40 in cell-mediated inflammatory responses. , 1996, Immunology today.

[31]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[32]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[33]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[34]  Kathleen R. Cho,et al.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[36]  R. Siliciano,et al.  Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. , 1995, Journal of immunology.

[37]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[38]  T. Elliott,et al.  Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum , 1995, The Journal of experimental medicine.

[39]  J. Yewdell,et al.  Trimming of antigenic peptides in an early secretory compartment , 1994, The Journal of experimental medicine.

[40]  J. Banchereau,et al.  Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.

[41]  S. Forman,et al.  Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? [see comments] , 1994 .

[42]  S. Riddell,et al.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes , 1994, Journal of medical virology.

[43]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[44]  S. Forman,et al.  Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? , 1994, Blood.

[45]  R. Schinazi,et al.  Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  F. Guarnieri,et al.  The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. , 1993, The Journal of biological chemistry.

[47]  B. Chain,et al.  Endocytosis by antigen presenting cells: dendritic cells are as endocytically active as other antigen presenting cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[49]  M. Fukuda,et al.  Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. , 1991, The Journal of biological chemistry.

[50]  P. Cresswell,et al.  Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I- restricted cell-mediated lysis , 1991, The Journal of experimental medicine.

[51]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[52]  M. Fukuda,et al.  Accumulation of membrane glycoproteins in lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail , 1990, The Journal of cell biology.

[53]  J. Yewdell,et al.  The binary logic of antigen processing and presentation to T cells , 1990, Cell.

[54]  P. Cresswell,et al.  Role for intracellular proteases in the processing and transport of class II HLA antigens. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[55]  B. Barrell,et al.  Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus , 1987, Journal of virology.

[56]  N. Flournoy,et al.  Risk factors for cytomegalovirus infection after human marrow transplantation. , 1986, The Journal of infectious diseases.

[57]  I. Pastan,et al.  Identification of two lysosomal membrane glycoproteins , 1985, The Journal of cell biology.

[58]  A. Helenius,et al.  Glycoproteins of the lysosomal membrane , 1985, The Journal of cell biology.